Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: Results of a phase II trial

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 249-256

  Kim, Hye Jin ^a   Yoon, Sung Soo ^b   Lee, Dong Soon ^b   Sohn, Sang Kyun ^c   Eom, Hyeon Seok ^d   Lee, Jung Lim ^e   Chung, Joo Seup ^f   Kim, Kihyun ^g   Suh, Cheolwon ^h   Won, Jong Ho ⁱ   Kim, Jin Seok ^j   Park, Joon Seong ^k   Kang, Hye Jin ^l   Seong, Chu Myong ^m   Kim, Cheol Soo ⁿ   Lee, Sang Jae ^o   Lee, Jae Hoon ^p  

^a The Armed Forces Capital Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d National Cancer Center   (South Korea)

^e Daegu Fatima Hospital   (South Korea)

^f Pusan National University Hospital   (South Korea)

^g Sungkyunkwan University   (South Korea)

^h Asan Medical Center   (South Korea)

ⁱ Soonchunhyang University College of Medicine   (South Korea)

^j Yonsei University College of Medicine   (South Korea)

^k Ajou University Medical Center   (South Korea)

^l Korea Institute of Radiation and Medical Science   (South Korea)

^m Ewha Womans University   (South Korea)

ⁿ Inha University Hospital   (South Korea)

^o Chung Ang University College of Medicine   (South Korea)

^p Gachon University College of Medicine   (South Korea)

more..

Author keywords

Bortezomib; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CD34 SELECTION; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ARREST; HERPES ZOSTER; HUMAN; INFECTION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84857363858     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1298-9     Document Type: Article

References (49)

1. RA Kyle SV Rajkumar 2004 Multiple myeloma N Engl J Med 351 18 1860 1873 15509819 10.1056/NEJMra041875 1:CAS:528:DC%2BD2cXptFChtLk%3D (Pubitemid 39426321)
2. SV Rajkumar RA Kyle 2005 Multiple myeloma: diagnosis and treatment Mayo Clin Proc 80 10 1371 1382 16212152 10.4065/80.10.1371 (Pubitemid 41395971)
3. L Savage 2007 Unreported VA data may affect SEER research, cancer surveillance, and statistics gathering J Natl Cancer Inst 99 23 1744 1745 18042924 10.1093/jnci/djm260 1752
4. M Attal, et al. 1996 A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome N Engl J Med 335 2 91 97 8649495 10.1056/NEJM199607113350204 1:STN:280:DyaK283ms1emuw%3D%3D (Pubitemid 26240110)
5. JA Child, et al. 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 19 1875 1883 12736280 10.1056/NEJMoa022340 1:CAS:528:DC%2BD3sXjsVChtLo%3D (Pubitemid 36532313)
6. A Palumbo, et al. 2004 Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial Blood 104 10 3052 3057 15265788 10.1182/blood-2004-02-0408 1:CAS:528: DC%2BD2cXhtVWhur%2FK (Pubitemid 39507119)
7. R Alexanian B Barlogie S Tucker 1990 VAD-based regimens as primary treatment for multiple myeloma Am J Hematol 33 2 86 89 2301376 10.1002/ajh.2830330203 1:STN:280:DyaK3c7ksVKquw%3D%3D (Pubitemid 20040083)
8. B Sirohi R Powles 2004 Multiple myeloma Lancet 363 9412 875 887 15031034 10.1016/S0140-6736(04)15736-X (Pubitemid 38368839)
9. L Mileshkin, et al. 2003 Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age Blood 102 1 69 77 12637329 10.1182/blood-2002-09-2846 1:CAS:528: DC%2BD3sXltFemtLc%3D (Pubitemid 36759637)
10. MA Dimopoulos, et al. 2001 Thalidomide and dexamethasone combination for refractory multiple myeloma Ann Oncol 12 7 991 995 11521808 10.1023/A: 1011132808904 1:STN:280:DC%2BD3MvnvVegsg%3D%3D (Pubitemid 32725775)
11. D Dingli, et al. 2005 Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial Haematologica 90 12 1650 1654 16330438 1:CAS:528:DC%2BD28XltVeitg%3D%3D (Pubitemid 41814989)
12. SV Rajkumar, et al. 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 3 431 436 16365178 10.1200/JCO.2005.03.0221 1:CAS:528: DC%2BD28XhsFSku7s%3D (Pubitemid 46630462)
13. J Adams, et al. 1999 Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res 59 11 2615 2622 10363983 1:CAS:528:DyaK1MXjs1ymsbY%3D (Pubitemid 29269108)
14. PG Richardson, et al. 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2609 2617 12826635 10.1056/NEJMoa030288 1:CAS:528:DC%2BD3sXkvVSksLs%3D (Pubitemid 36741588)
15. PG Richardson, et al. 2006 Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial Cancer 106 6 1316 1319 16470606 10.1002/cncr.21740 1:CAS:528:DC%2BD28XjtVCrsLc%3D (Pubitemid 43363908)
16. S Jagannath, et al. 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 2 165 172 15461622 10.1111/j.1365-2141.2004.05188.x 1:CAS:528:DC%2BD2cXpvFait7g%3D (Pubitemid 39371809)
17. S Jagannath, et al. 2006 Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone Haematologica 91 7 929 934 16818280 1:CAS:528:DC%2BD28XnslSmsrg%3D (Pubitemid 44023146)
18. PG Richardson, et al. 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 24 2487 2498 15958804 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D (Pubitemid 41007864)
19. PG Richardson, et al. 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 10 3557 3560 17690257 10.1182/blood-2006-08-036947 1:CAS:528: DC%2BD2sXhtlarur3K (Pubitemid 350159621)
20. S Jagannath, et al. 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 6 776 783 15953004 10.1111/j.1365-2141.2005.05540.x 1:CAS:528:DC%2BD2MXms1ehsLw%3D (Pubitemid 40904528)
21. M Pineda-Roman, et al. 2008 VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma Leukemia 22 7 1419 1427 18432260 10.1038/leu.2008.99 1:CAS:528:DC%2BD1cXosFSms78%3D (Pubitemid 352006086)
22. M Cavo, et al. 2010 Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 9758 2075 2085 21146205 10.1016/S0140-6736(10)61424-9 1:CAS:528:DC%2BC3cXhsFynurvK
23. M Cavo, et al. 2011 International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation Blood 117 23 6063 6073 21447828 10.1182/blood-2011-02-297325 1:CAS:528:DC%2BC3MXotVyiurg%3D
24. GL Uy, et al. 2009 Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study Bone Marrow Transplant 43 10 793 800 19029964 10.1038/bmt.2008.384 1:CAS:528:DC%2BD1MXmsVGjt78%3D
25. BG Durie, et al. 2006 International uniform response criteria for multiple myeloma Leukemia 20 9 1467 1473 16855634 10.1038/sj.leu.2404284 1:STN:280:DC%2BD28rgt1aqtA%3D%3D (Pubitemid 44264086)
26. A Trotti, et al. 2003 CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 3 176 181 12903007 10.1016/S1053-4296(03)00031-6 (Pubitemid 36962641)
27. JS Kim, et al. 2009 Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation Biol Blood Marrow Transplant 15 4 463 470 19285634 10.1016/j.bbmt.2008.12.512 1:CAS:528: DC%2BD1MXkslKhur0%3D
28. B Barlogie, et al. 2008 Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma Cancer 113 2 355 359 18470907 10.1002/cncr.23546
29. N Raje, et al. 1997 A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma Br J Haematol 97 1 153 160 9136958 10.1046/j.1365-2141.1997.d01-2122.x 1:CAS:528:DyaK2sXjtFKnsb4%3D (Pubitemid 27179580)
30. P Moreau, et al. 2002 Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial Blood 99 3 731 735 11806971 10.1182/blood.V99.3.731 1:CAS:528:DC%2BD38XhtVals7o%3D (Pubitemid 34525530)
31. M Cavo, et al. 2005 Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma Blood 106 1 35 39 15761019 10.1182/blood-2005-02-0522 1:CAS:528:DC%2BD2MXlvVWjs78%3D (Pubitemid 40967171)
32. MA Hussein, et al. 2009 Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204) J Clin Oncol 27 21 3510 3517 19546405 10.1200/JCO.2008.19.9240 1:CAS:528:DC%2BD1MXhtVSqtLjP
33. JL Harousseau, et al. 2006 Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study Haematologica 91 11 1498 1505 17043025 1:CAS:528:DC%2BD28XhtlSltb%2FN
34. JL Harousseau, et al. 2010 Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial J Clin Oncol 28 30 4621 4629 20823406 10.1200/JCO.2009.27.9158 1:CAS:528:DC%2BC3cXhsFaitLzL
35. H Avet-Loiseau, et al. 2007 Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood 109 8 3489 3495 17209057 10.1182/blood-2006-08-040410 1:CAS:528: DC%2BD2sXksFWhsrk%3D (Pubitemid 46572539)
36. E Terpos V Eleutherakis-Papaiakovou MA Dimopoulos 2006 Clinical implications of chromosomal abnormalities in multiple myeloma Leuk Lymphoma 47 5 803 814 16753864 10.1080/10428190500464104 1:CAS:528:DC%2BD28Xms1Shtrc%3D (Pubitemid 43840635)
37. R Fonseca, et al. 2004 Genetics and cytogenetics of multiple myeloma: a workshop report Cancer Res 64 4 1546 1558 14989251 10.1158/0008-5472.CAN-03-2876 1:CAS:528:DC%2BD2cXhtleitb4%3D (Pubitemid 38235629)
38. R Fonseca, et al. 2002 Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients Blood 99 10 3735 3741 11986230 10.1182/blood.V99.10.3735 1:CAS:528:DC%2BD38XjvVGntr0%3D (Pubitemid 34534545)
39. PG Richardson, et al. 2005 Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Blood 106 9 2977 2981 16020506 10.1182/blood-2005-02-0691 1:CAS:528:DC%2BD2MXht1Wntr%2FM (Pubitemid 41565888)
40. S Jagannath, et al. 2007 Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials Leukemia 21 1 151 157 17096017 10.1038/sj.leu.2404442 1:CAS:528:DC%2BD28XhtlSqur3O (Pubitemid 44921846)
41. Mellqvist UHM et al (2009) Improved response rate with bortezomib consolidation after high dose melphalan: first results of a Nordic Myeloma Study Group randomized phase III trial. Blood 114(22) (Abstract 530)
42. A Palumbo, et al. 2008 Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma Leukemia 22 2 414 423 18094721 10.1038/sj.leu.2405062 1:CAS:528:DC%2BD1cXhvVyltLc%3D (Pubitemid 351255436)
43. Y Koh, et al. 2010 Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide Ann Hematol 89 2 201 206 19705118 10.1007/s00277-009-0807-6 1:CAS:528:DC%2BC3cXjt1yksA%3D%3D
44. A Abdelkefi, et al. 2005 First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma Bone Marrow Transplant 36 3 193 198 15968290 10.1038/sj.bmt.1705050 1:CAS:528:DC%2BD2MXmt1Wmsb4%3D (Pubitemid 41136290)
45. M Attal, et al. 2006 Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 10 3289 3294 16873668 10.1182/blood-2006-05-022962 1:CAS:528:DC%2BD28Xht1ahs7fE
46. Schiller G et al (2008) Phase I/II trial of bortezomib maintenance following autologous peripheral blood progenitor cell transplantation as treatment for intermediate-and advanced-stage multiple myeloma. Biol Blood Marrow Transplant 14, Absract 176
47. Sonneveld P et al (2010) HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs. VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood 116, Abstract 40
48. G Benevolo, et al. 2011 The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens Cancer 119 1884 1890 10.1002/cncr.25743
49. A Palumbo, et al. 2010 Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients J Clin Oncol 28 5 800 807 20048187 10.1200/JCO.2009.22.7561 1:CAS:528:DC%2BC3cXksVyrtro%3D